Treatment of chronic hepatitis B and chronic hepatitis C

Reviews in Medical Virology

Volumn 6, Issue 4, 1996, Pages 215-228

  Terrault, Norah A ^a  

^a SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALPHA INTERFERON; ALPHA2B INTERFERON; BETA INTERFERON; COLCHICINE; DIDANOSINE; FAMCICLOVIR; GAMMA INTERFERON; GANCICLOVIR; GUANOSINE DERIVATIVE; HEPATITIS B VACCINE; HEPATITIS C VACCINE; INTERLEUKIN 2; LAMIVUDINE; LOBUCAVIR; PENCICLOVIR; PROSTAGLANDIN E2; RIBAVIRIN; THYMOSIN ALPHA1; URSODEOXYCHOLIC ACID; ZIDOVUDINE;

CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; HEPATITIS B; HEPATITIS C; HUMAN; REVIEW;

EID: 0029951228     PISSN: 10529276     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-1654(199612)6:4<215::AID-RMV178>3.0.CO;2-J     Document Type: Review

References (144)

1. Poynard, T., Bedossa, P., Chevallier, M. et al. (1995). A comparison of three α-2b interferon regimes for long term treatment of chronic non-A non-B hepatitis. N. Engl. J. Med. 332, 1457-1462.
2. Nishigushi, S., Kuroki, T., Nakatani, S. et al. (1995). Randomised trial of effects of interferon-a on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 346, 1051-1055.
3. Hyams, K. C. (1995), Risks of chronicity following acute hepatitis B virus infection: A review. Clin. Infect. Dis. 20, 992-1000.
4. McMahon, B., Alward, W., Hall, D. et al. (1984). Acute hepatitis B virus infection, relation of age to the clinical expression of disease and subsequent development of the carrier state.J. Infect. Dis. 151, 599-603.
5. Seeff, L. B, Beebe, G. W., Hoofnagle, J. H. et al. (1987). A serological follow-up of the 1942 epidemic of post-vaccination hepatitis in the United States Army. N. Engl. J. Med. 316, 965-970.
6. De Jongh, F. E., Janssen, H. L. A., De Man, R. A., Hop, W. C. J., Schalm, S. W. and van Blankenstein, M. (1992). Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroentewlogy 103, 1630-1635.
7. Fattovich, G., Brollo, L., Giustina, G. et al. (1991). Natural history and prognostic factors for chronic hepatitis type B. Gut 32, 294-298.
8. Weissberg, J., Andres, L., Smith, C. et al. (1984). Survival in chronic hepatitis B: An analysis of 379 patients. Ann. Intern. Med. 101, 613-616.
9. Beasley, R. (1988). Hepatitis B. The major etiology of hepatocellular carcinoma. Cancer 61, 1942-1956.
10. de Franchis, R., Meucci, G., Vecchi, M. et al. (1993). The natural history of asymptomatic hepatitis B surface antigen carriers. Ann. Intern. Med. 118, 191-194.
11. Perrillo, R., Schiff, E., Davis, G. et al. (1990). A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N. Engl. J. Med. 323, 295-301.
12. Wong, D., Cheung, A., O'Rourke, K., Naylor, C., Detsky, A., Heathcote, J. (1993). Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann. Intern. Med. 119, 312-323.
13. Carreno, V., Castillo, I., Molina, J., Porres, J. and Bartolome, J. (1992). Long-term follow-up of hepatitis B chronic carriers who responded to interferon therapy. J. Hepatol. 15, 102-106.
14. Korenman, J., Baker, B., Waggoner, J., Everhart, J., DiBisceglie, A. and Hoofnagle, J. (1991). Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann. Mem. Med. 114, 629-634.
15. Lok, A., Chung, H., Liu, V. and Ma, O. (1993). Long-term follow-up of chronic hepatitis B patients treated with interferon alfa. Gastroenterol-ogy 105, 1833-1838.
16. 15a. Coppens, J. P., Cornu, C., Lens, E., Lamy, M. and Geubel, A. P. (1990). Prospective trial of recombinant leukocyte interferon in chronic hepatitis B: a long-term study. J. Hepatol. 11, S126-S128.
17. Perrillo, R. and Brunt, E. (1991). Hepatic histologie and immunohistochemical changes in chronic hepatitis B after prolonged clearance of hepatitis B e antigen and hepatitis B surface antigen. Ann. Intern. Med. 115, 113-115.
18. Kuhns, M., McNamara, A., Mason, A., Campbell, C. and Perrillo, R. (1992). Serum and liver hepatitis B virus DNA in chronic hepatitis B after sustained loss of surface antigen. Gastroenterobgy 103, 1649-1656.
19. Lok, A., Lai, C. and Lau, J. (1991). Interferon alfa therapy in patients with chronic hepatitis B virus infection. Effects on hepatitis B virus DNA in the liver. Gastroenterology 100, 756-761.
20. Bruch, H., Korn, A., Klein, H. et al. (1993). Treatment of chronic hepatitis B with interferon a-2b and interleukin-2. J. Hepatol. 17, S52-S55.
21. DiBisceglie, A., Rustgi, V., Kassianides, C. et al. (1990). Therapy of chronic hepatitis B with recombinant human alpha and gamma interferon. Hepatology 11, 266-270.
22. Fattovich, G., Giustina, G., Brollo, L. et al. (1992). Therapy for chronic hepatitis B with lymphoblastoid interferon-a and levamisole. Hepatology 16, 1115-1119.
23. Garcia, G., Smith, C., Weissberg, J. et al. (1987). Adenine arabinoside monophosphate (vidarabine phosphate) in combination with human leukocyte interferon in the treatment of chronic hepatitis B. Ann. Intern. Med. 107, 278-285.
24. Janssen, H., Berk, L., Heijtink, R., Ten Kate, F. and Schalm, S. (1993). Interferon-α and zidovudine combination therapy for chronic hepatitis B: Results of a randomized, placebo-controlled trial. Hepatology 17, 383-388.
25. Lau, J., Lai, C., Wu, P., Chung, H., Lok, A. and Lin, H. (1991). A randomised controlled trial of recombinant interferon-γ in Chinese patients with chronic hepatitis B virus infection. J. Med. Virol. 34, 184-187.
26. Rasi, G., Mutchnick, M., DiVirgilio, D. et al. (1994). Combination low-dose lymphoblastoid interferon and thymosin al therapy in the Treatment of chronic hepatitis B. Hepatology 20, 299A.
27. Brook, M., Karayiannis, P. and Thomas H. (1989). Which patients with chronic hepatitis B virus infection will respond to α-interferon therapy? A statistical analysis of predictive factors. Hepatology 10, 761-763.
28. Zaaijer, H., Ter Borg, F., Cuypers, H., Hermus, M. and Lelie, P. (1994). Comparison of methods for detection of hepatitis B virus DNA. J. Clin. Microbiol. 32, 2088-91.
29. Lok, A., Lai, C., Wu, P.and Leung, E. (1988). Long-term follow-up of a randomised controlled trial of recombinant alpha 2-interferon in Chinese patients with chronic hepatitis B infection. Lancet 2, 298-302.
30. Lok, A., Wu, P., Lau, J., Leung, E. and Wong, L. (1989). Treatment of chronic hepatitis B with interferon: experience with Asian patients. Sem. Liver. Dis. 9, 249-253.
31. Lai, C., Lok, A., Lin, H., Wu, P., Yeoh, E. and Yeung, C. (1987). Placebo-controlled trial of recombinant a2-interferon in Chinese HBsAg-carrier children. Lancet 2, 877-880.
32. McDonald, J., Caruso, L., Karayiannis, P. et al. (1987). Diminished responsiveness of male homosexual chronic hepatitis B virus carriers with HTLV-III antibodies to recombinant a-interferon. Hepatology 7, 719-723.
33. Krogsgaard, K., Bindslev, N., Christensen, E. et al. (1994). The treatment effect of alpha interferon in chronic hepatitis B is independent of pre-treatment variables. Results based on individual patient data from 10 clinical controlled trials. European Concerted Action on Viral Hepatitis (Eurohep). J. Hepatol. 21, 646-655.
34. Lok, A., Weller, I., Karayiannis, P. et al. (1984). Thrice weekly lymphoblastoid interferon is effective in inhibiting hepatitis B virus replication. Liver 4, 45-49.
35. Weller, I., Bassendine, M., Craxi, A. et al. (1982). Successful treatment of HBs and HBeAg positive chronic liver disease: prolonged inhibition of viral replication by highly soluble adenine arabinoside 5′-monophosphate (ARA-AMP). Gut 23, 717-723.
36. Hoofnagle, J., DiBisceglie, A., Waggoner, J. and Park, Y. (1993). Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B. Gastroenterology 104, 1116-1121.
37. Nevens, F., Goubau, P., Van Eyken, P., Desmyter, J. and Fevery J. (1993). Treatment of decompensated viral hepatitis B-induced cirrhosis with low doses of interferon. Liver 13, 15-19.
38. Dusheiko, G. and Roberts, J. (1995). Treatment of chronic type B and C hepatitis with interferon alfa: an economic appraisal. Hepatology 22, 1863-1873.
39. Wong, J. B, Koff, R. S., Tine, F and Pauker, S. G. (1995). Cost-effectiveness of interferon-alpha 2b treatment for hepatitis B e antigen-positive hepatitis B. Ann. Intern. Med. 122, 664-675.
40. Tyrrell, D., Mitchell, M., De Man, R. et al. (1993). Phase II trial of lamivudine for chronic hepatitis B. Hepatology 18, 112A.
41. Dienstag, J. L., Perrillo, R. P., Schiff, E. R., Bartholomew, M., Vicary, C. and Rubin, M. (1995). A preliminary trial of lamivudine for chronic hepatitis B infection. N. Engl J. Med. 333, 1657-1661.
42. Berk, L., Schalm, S., de Man, R. et al. (1992). Failure of acyclovir to enhance the antiviral effect of a lymphoblastoid interferon on HBe-seroconversion in chronic hepatitis B. A multi-centre randomized controlled trial. J. Hepatol. 305-309.
43. Chossegros, P., Pouteil-Noble, C., Causse, X., Pouyet, M., Touraine, J. and Trepo, C. (1992). Ganciclovir is an effective antiviral agent for posttransplant chronic HBV infection but maintenance therapy is required. J. Hepatol. 16 (Suppl. 1), S9.
44. Gish, R., Lau, J. Y., Brooks, L. et al. (1996). Ganciclovir treatment of hepatitis B virus infection in liver transplant recipients. Hepatology 23, 1-7.
45. Perry, C. M. and Wagstaff, A. J. (1995). Famciclovir. A review of its pharmacological properties and therapeutic efficacy in herpesvirus infections. Drugs 50, 396-415.
46. Korba, B. and Gerin, J. (1992). Use of a standardized cell culture assay to assess activities of nucleoside analogs against hepatitis B virus replication. Antiv. Res. 17, 1-16.
47. Shaw, T., Amor, P., Civitico, G., Boyd, M. and Locarnini, S. (1994). In vitro antiviral activity of penciclovir, a novel purine nucleoside, against duck hepatitis B virus. Anlimicrob. Agents Chem-other. 38, 719.
48. Tsiquaye, K. (19 ). Famciclovir prophylaxis of acute duck hepatitis B virus (HBDV) infection in pekin ducklings. Proceedings of 1993 International Symposium on Viral Hepatitis and Liver Disease, The 8th Triennial Congress, 1993: A223.
49. Angus, P., Neuhaus, P., Manns, M. et al. (1995). An open study to assess the effect of famciclovir on hepatitis B replication in patients who have received an orthotopic liver transplant. AASLD Single Topic Symposium, Reston, VA.
50. Boker, K., Ringe, B., Kruger, M., Pichlamyr, R. and Manns, M. P. (1994). Prostaglandin E plus famciclovir - a new concept for the treatment of severe hepatitis B after liver transplantation. Transplantation 57, 1706-1708.
51. Kruger, M., Tillmann, H., Trautwein, C. et al. (1994). Treatment of hepatitis B virus reinfection after liver transplantation with famciclovir. Hepatology 20, 130A.
52. Boike, S., Pue, M., Freed, M. et al. (1994). Pharmacokinetics of famciclovir in subjects with varying degrees of renal impairment. Clin. Pharmacol. Ther. 55, 418-426.
53. Product Monograph (1994). Famvir™ (Famciclovir), for the Treatment of Acute Herpes Zoster. SmithKline Beecham Pharmaceuticals pp. 13-42.
54. Abrams, D., Goldman, A., Launer, C. et al. (1994). A comparative trial of didanosine or zalcitabine after treatment with zidovudine in patients with human immunodeficiency virus infection. N. Engl J. Med. 330, 657.
55. McKensie, R., Fried, M., Sallie, R. et al. (1995). Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N. Engl. J. Med. 333, 1099-2015.
56. Coffin, E., Horsmans,Y., Pirson, Y., Cornu, C., Geubil, A. and van Ypersele De Strihou, C. (1995). Acute necrotico-hemorrhagic pancreatitis after famciclovir prescription. Transplantation 59, 1218-1219.
57. Vitiello, A., Ishioka, G., Grey, H. el at. (1995). Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. J. Clin. Invest. 95, 341-349.
58. Low, T. and Goldstein, A. (1984). Thymosins: structure, function and therapeutic applications. Thymus 6, 27-42.
59. Wetzel, R., Heyneker, H., Goeddel, D. et al. (1980). Production of biologically active Na-desacetlythymosin al in E. coli through expression of a chemically synthesized gene. Biochemistry 19, 6096-6104.
60. Mutchnick, M., Appelman, H., Chung, H. et al. (1991). Thymosin treatment of chronic hepatitis B: a placebo-controlled pilot study. Hepatology 14, 409-415.
61. Mutchnick, M., Lindsay, K., Schiff, E, Cummings G. and Appelman H. (1995). Thymosin alpha1 treatment of chronic hepatitis B: A multicenter, randomized, placebo-controlled double blind study. Gastroenterology 108, A1127.
62. Kagawa, T., Morizane, T., Saito, H. et al. (1993). A pilot study of long-term weekly interferon-β-administration for chronic hepatitis B. Am. J. Gastwenterol. 88, 212-216.
63. Kakuma, S., Ishikawa, T., Mirokami, M. et al. (1991). Treatment of human gamma interferon for chronic hepatitis B: Comparative study with alpha interferon. J. Med. Virol. 35, 32-37.
64. Marcellin, P., Loriot, M., Boyer, N. et al. (1990). Recombinant human γ-interferon in patients with chronic active hepatitis B: Pharma-cokinetics, tolerance and biological effects. Hepatology 12, 155-158.
65. Caselmann, W., Eisenburg, J., Hofschneider, P. and Koshy, R. (1989). β- and γ-interferon in chronic active hepatitis B. Gastroenterology 96, 449-455.
66. Lam, K., Lai, C., Trepo, C. and Wu, P. (1980). Deleterious effect of prednisolone in HBsAg-positive chronic active hepatitis. N. Engl J. Med. 304, 380-384.
67. Realdi, G., Alberti, A., Rugge, M. et al. (1980). Seroconversion from hepatitis B e antigen to anti-HBe in chronic hepatitis B infection. Gastroenterohgy 79, 195-199.
68. Nair, P., Tong, M., Stevenson, D., Roskamp, D. and Boone, C. (1985). Effect of short-term, highdose prednisone treatment of patients with HBsAg-positive chronic active hepatitis. Liver 5, 8-12.
69. Scullard, G., Smith, C., Merigan, T., Robinson, W. and Gregory, P. (1981). Effects of immunosuppressive therapy on viral markers in chronic active hepatitis B. Gastroenterology 81, 987-991.
70. Fevery, J., Elewaut, A., Michielson, P. et al. (1990). Efficacy of interferon alfa-2b with or without prednisone withdrawal in the treatment of chronic viral hepatitis B. A prospective doubleblind Belgian-Dutch study. J. Hepatol. 11, S108-S112.
71. Gregorio, G., Jara, P., Hierro, L. et al. (1996). Lymphoblastoid interferon alfa with or without steroid pretreatment in children with chronic hepatitis B: A multicenter controlled trial. Hepatology 23, 700-707.
72. Lok, A., Wu, P., Lai, C. et al. (1992). A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. Gastroenterology 102, 2091-2097.
73. Ferez, V., Findor, J., Tanno, H. and Sorda, J. (1993). A controlled trial of high dose interferon, alone and after prednisone withdrawal, in the treatment of chronic hepatitis B: long term follow-up. Gut 34 (Suppl. 2), S91-94.
74. Zarski, J., Causse, X., Cohard, M., Cougnard, J. and Trepo, C. (1994). A randomized, controlled trial of interferon alfa-2b alone and with simultaneous prednisone for the treatment of chronic hepatitis B. French Multicenter Group. J. Hepatol. 20, 735-741.
75. Fattovich, G., Brollo, L., Pontisso, P. et al. (1986). Levamisole therapy in chronic type B hepatitis. Results of a double-blind randomized trial. Gastroenterology 91, 692-696.
76. Venkateswaran, P., Millman, I. and Blumberg, B. (1986). Effects of an extract from Phyllanthus niruri on hepatitis B and woodchuck hepatitis B viruses: In vitro and in vivo studies. Proc. Natl. Acad. Sci. USA 84, 274-278.
77. Thyagarajan, S., Subramanian, S., Thirunalasundari, T., Venkateswaran, P. and Blumberg, B. (1988). Effects of Phyllanthus amarus on chronic carriers of hepatitis B virus. Lancet 2, 764-766.
78. Wang, Y., Lee, S., Hsieh, M. et al. (1994). A double-blind randomized controlled trial of colchicine in patients with hepatitis B virus-related postnecrotic cirrhosis. J. Hepatol. 21, 872-877.
79. Catterall, A., Moyle, G., Hopes, E., Harrison, T., Gazzard, B. and Murray-Lyon, I. (1992). Dideoxyinosine for chronic hepatitis B infection. J. Med. Virol. 37, 307-309.
80. Cerenzia, M., Fiume, L., De Barnardi Venon, W. et al. (1996). Adenine arabinoside monophosphate coupled to lactosaminated human albumin administered for 4 weeks in patients with chronic type B hepatitis decreased viremia without producing significant side effects. Hepatology 23, 657-661.
81. Kakumu, S., Fuji, A., Yoshioka, K. et al. (1988). Pilot study of recombinant human interleukin 2 for chronic type B hepatitis. Hepatology 8, 487-492.
82. Nishioka, M., Kagawa, H., Shirai, M., Terada, S. and Watanabe, S. (1987). Effects of human recombinant interleukin 2 in patients with chronic hepatitis B: A preliminary report. Am. J. Gastroenterol. 82, 438-442.
83. Onji, M., Kondoh, H., Horiike, N. et al. (1987). Effect of recombinant interleukin 2 on hepatitis B e antigen positive chronic hepatitis. Gut 28, 1648-1652.
84. Schalm, S., Heytink, R., van Buuren, H. and de Mann, R. (1985). Acyclovir enhances the antiviral effect of interferon in chronic hepatitis B. Lancet 2, 358-360.
85. Tong, M., Hwang, S., Lefkowitz, M., Lee, S., Co, R. and Lo, K. (1995). A pilot, open labelled, phase II study using ribavirin in the treatment of patients with chronic active hepatitis B. Clin. Diag. Virol. in press.
86. Alter, H. (1995). To C or not to C: These are the questions. Blood 85, 1681-1695.
87. Brillanti, S., Foli, M., Gaiani, S., Masci, C., Miglioli, M. and Barbara, L. (1993). Persistent hepatitis C viraemia without liver disease. Lancet 341, 464-465.
88. Naito, M., Hayashi, N., Hagiwara, H. et al. (1994). Serum hepatitis C virus RNA quantity and histological features of hepatitis C virus carriers with persistently normal ALT. Hepatology 19, 871-875.
89. Koretz, R., Abbey, H., Coleman, E. and Gitnick, G. (1993). Non-A, non-B post-transfusion hepatitis: Looking back in the second decade. Ann. Intern. Med. 119, 110-115.
90. Seeff, L. and the NHLBI Study Group. (1994). Mortality and morbidity of transfusion-associated non-A, non-B (NANB) and type C hepatitis. Hepatology 20, 264A.
91. Kiyosawa, K., Sodeyama, T., Tanaka, E. et al. (1990). Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 12, 671-675.
92. Tong, M., El-Farra, N., Reikes, A. and Co, R. (1995). Clinical outcomes after transfusion-associated hepatitis C infection. N. Engl J. Med.
93. Seeff, L., Buskell-Bales, Z., Wright, E. et al. (1992). Long-term mortality after transfusion-associated non-A, non-B hepatitis. N. Engl J. Med. 327, 1906-1911.
94. Davis, G., Baiart, L., Schiff, E. et al. (1989). Treatment of chronic hepatitis C with recombinant interferon alfa. N. Engl J. Med. 321, 1501-1506.
95. DiBisceglie, A., Marin, P., Kassianides, C. et al. (1989). Recombinant interferon alfa therapy for chronic hepatitis C: A randomized, double-blind, placebo-controlled trial. N. Engl J. Med. 321, 1506-1510.
96. Tine, F., Magrin, S., Craxi, S. and Pagliaro, L. (1991). Interferon for non-A non-B chronic hepatitis: A meta-analysis of randomized clinical trials. J. Hepatol. 13, 192-199.
97. Chemello, L., Bonetti, P., Cavalletto, L. et al. (1995). Randomized trial comparing three different regimes of alpha-2a-interferon in chronic hepatitis C. Hepatology 22, 700-706.
98. Shindo, M., Arai, K., Sokawa, Y. and Okuno, T. (1995). Hepatic hepatitis C virus RNA as a predictor of a long term response to interferon alfa therapy. Ann. Intern. Med. 122, 586-591.
99. Kobayashi, Y., Watanabe, S., Konishi, M. et al. (1992). Detection of hepatitis C virus RNA by nested polymerase chain reaction in sera of patients with chronic non-A, non-B hepatitis treated with interferon. J. Hepatol. 16, 138-144.
100. Lau, J., Mizokami, M., Ohno, T., Diamond, D., Kniffen, J. and Davis, G. (1993). Discrepancy between biochemical and virological responses in interferon-alpha in chronic hepatitis C. Lancet 342, 1208-1209.
101. Balart, L., Perrillo, R., Roddenbeny, J. et al. (1993). Hepatitis C RNA in liver of chronic hepatitis C patients before and after interferon alfa treatment. Gastroenterology 104, 1472-1477.
102. Gurakar, A., Fagiuoli, S., Faruki, H. et al (1995). Utility of hepatitis C virus RNA determination in hepabic tissue as an end point for interferon treatment of chronic hepatitis C. Hepatology 22, 1109-1112.
103. Causse, X., Godinot, H., Chevallier, M. et al. (1991). Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A non-B hepatitis. Gastroenterology 101, 497-502.
104. Enomoto, N., Sakuma, I., Asahina, Y. et al. (1996). Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Eng. J. Med. 334, 77-81.
105. Kanazawa, Y., Hayashi, N., Mita, E. el al. (1994). Influence of viral quasispecies on effectiveness of interferon therapy in chronic hepatitis C patients. Hepatology 20, 1121-1130.
106. Koizumi, K., Enomoto, N., Kurosaki, M. et al. (1995). Diversity of quasispecies in various disease stages of chronic hepatitis C virus infection and its significance in interferon treatment. Hepatology 22, 30-35.
107. Olynyk, J., Reddy, K., DiBisceglie, A. et al. (1995). Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitis C. Gastroenterology 108, 1104-1109.
108. Pagliaro, L., Craxi, A., Camma, C. et al. (1994). Interferon-alpha for chronic hepatitis C: an analysis of pretreatment clinical predictors of response, Hepatology 19, 820-828.
109. Hayashi, J., Ohmiya, M., Kishihara, Y. et al. (1994). A statistical analysis of predictive factors of response to human lymphoblastoid interferon in patients with chronic hepatitis C. Am J Gastroenlerol 89, 2151-2156.
110. Kasahara, A., Hayashi, N., Hiramatsu, N. et al. (1995). Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: A multicenter randomized controlled trial. Hepatology 21, 291-297.
111. Lau, J., Davis, G., Kniffen, J. et al. (1993). Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 341, 1501-1504.
112. Martinot-Peignoux, M., Marcellin, P., Pouteau, M. et al. (1995). Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology 22, 1050-1056.
113. Nousbaum, J., Pol, S., Nalpas, B. et al. (1995). Hepatitis C virus type 1b (II) infection in France and Italy. Ann. Intern. Med. 122, 161-168.
114. Tsubota, A., Chayama, K., Ikeda, K. et al. (1994). Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection. Hepatology 19, 1088-1094.
115. Yamada, G., Takatani, M., Kishi, F. et al. (1995). Efficacy of interferon alfa therapy in chronic hepatitis C patients depends primarily on hepatitis C virus RNA level. Hepatology 22, 1352-1354.
116. Yun, Z., Reichard, O., Chen, M. et al. (1994). Serum hepatitis C virus RNA levels in chronic hepatitis C - Importance for outcome of interferon alfa-2b treatment. Scand J Infect Dis 26, 263-270.
117. 115a. Hino, K., Okuda, M., Konishi, T., Ishiko, H. and Okita, K. (1995). Serial assay of hepatitis C virus RNA in serum for predicting response to interferon alfa therapy. Dig. Dis. Sci. 40, 14-20.
118. Jouet, P., Roudot-Thoraval, F., Dhumeaux, D. et al. (1994). Comparative efficacy of interferon alfa in cirrhotic and noncirrhotic patients with non-A, non-B, C hepatitis. Gastroenterology 106, 686-690.
119. Lin, R., Schoeman, M., Craig, P. et al. (1991). Can the response to interferon treatment be predicted in patients with chronic active hepatitis C? Aust. N.Z. J. Med. 21, 387-392.
120. Uchida, T., Taira, M., Shikata, T. et al. (1993). Histological difference between complete responders and non-responders to interferon therapy of the livers of patients with chronic hepatitis C. Acta Pathol. Japon. 43, 230-236.
121. Lindsay, K., Davis, G., Schiff, E. et al. (1993). Long-term response to higher doses of interferon alfa-2b treatment of patients with chronic hepatitis C: A randomized multicenter trial. Hepatology 18, 106A.
122. Craxi, A., Almasio, P. and Di Marco, V. (1996). Moving towards optimal treatment of hepatitis C. Triennial International Symposium on Viral Hepatitis and Liver Disease, Rome, Italy, April 21-5, 1996.
123. Poynard, T., Leroy, V., Cohard, M., Mathurin, P., Opolon, P. and Zarski, J. (1995). Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C. Effects of dose and duration. Hepatology 22, 113A.
124. Marcellin, P., Pouteau, M., Martinot-Peignoux, M. et al. (1995). A lack of benefit of escalating dosage of interferon alfa in patients with chronic hepatitis C. Gastroenterology 109, 156-165.
125. Diodati, G., Bonetti, P., Noventa, F. et al. (1994). Treatment of chronic hepatitis C with recombinant human interferon-α2a: Results of a randomized controlled clinical trial. Hepatology 19, 1-5.
126. Koff, R. and Seeff, L. (1995). Economic modeling of treatment of chronic hepatitis B and chronic hepatitis C: Promises and limitations. Hepatology 22, 1880-1882.
127. Bennett, W., Inoue, Y., Beck, J., Pauker, S. and Davis, G. (1995). Justification of a single 6-month course of interferon for histologically mild chronic hepatitis C. Hepatology 22, 290A.
128. Saez-Royuela, F., Poires, J., Moreno, A. et al. (1991). High doses of recombinant α-interferon and γ-interferon for chronic hepatitis C: A rand-omized, controlled trial. Hepatology 13, 327-331.
129. Ohnishi, K., Nomura, F. and Iida, S. (1989). Treatment of posttransfusion non-A, non-B acute and chronic hepatitis with human fibroblast β-interferon: a preliminary report. Am. J. Gaestroenterol 84, 596-600.
130. Ferez, R., Pravia, R., Artimez, M. et al. (1995). Clinical efficacy of intramuscular human interferonbeta vs interferon-alpha 2b for the treatment of chronic hepatitis C. J. Viral. Hep. 2, 103-106.
131. Takano, S., Satomura, Y., Omata, M. et al. (1994). Effects of Interferon beta on non-A non-B acute hepatitis: a prospective, randomized, controlleddose study. Gastroenterology 107, 805-811.
132. DiBisceglie, A., Conjeevaram, H., Fried, M. et al. (1995). Ribavirin as therapy for chronic hepatitis C. Ann. Intern. Med. 123, 897-903.
133. DiBisceglie, A., Bacon, B., Kleiner, D. and Hoofnagle, J. (1994). Increase in hepatic iron stores following prolonged therapy with ribavirin in patients with chronic hepatitis C. J. Hepatol. 21, 1109-1112.
134. Brillanti, S., Garson, J., Foli, M et al. (1994). A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C. Gastroenterology 107, 812-817.
135. Schvarcz, R., Yun, Z., Sonnerborg, A. and Weiland, O. (1995). Combined treatment with interferon α-2b and ribavirin for chronic hepatitis C in patients with a previous non-response or non-sustained response to interferon alone. J. Med. Virol. 46, 43-47.
136. Arber, N., Moshkowitz, M., Konikoff, F. et al (1995). Elevated serum iron predicts response to interferon treatment in patients with chronic HCV infection. Dig. Dis. Sci. 40, 2431-2433.
137. Bacon, B., Rebholz, A., Fried, M. and DiBisceglie, A. (1993). Beneficial effect of iron reduction therapy in patients with chronic hepatitis C who failed to respond to interferon alpha. Hepatology 18, 150A.
138. Hayashi, H., Takikawa, T., Nishimura, N., Yano, M., Isomura, T. and Sakamoto, N. (1994). Improvement of serum aminotransferase levels after phlebotomy in patients with chronic active hepatitis C and excess hepatic iron. Am. J. Gastroenterol. 89, 986-988.
139. Boucher, E., Jouanoile, H., Andre, P. et al. (1995). Interferon and ursodeoxycholic acid combined therapy in the treatment of chronic viral C hepatitis: Results from a controlled randomized trial in 80 patients. Hepatology 21, 322-327.
140. Liaw, Y., Sheen, I., Lin, S., Chen, T. and Chu, C. (1993). Effects of prednisolone pretreatment in interferon alfa therapy for patients with chronic non-A, non-B (C) hepatitis. Liver 13, 46-50.
141. Andreone, P., Cursaro, C., Gramenzzi, A. et al. (1993). Alfa-interferon plus indomethacin combined therapy for non-responder patients with chronic hepatitis C. Hepatology 18, 221A.
142. Naito M, Kashiwagi M, Nagasawa M. et al. (1995). Combination therapy of interferon and glycyrrhizin in patients with chronic hepatitis C. Hepatology 22, 461A.
143. Sherman, K., Sjogren, M., Creager, R. et al. (1994). Hepatitis C RNA response to combined therapy with thymosin alpha-l and interferon. Hepcilology 20, 207A.
144. Trande, P., Esposito, P., Marchi, S. et al. (1995). Double-blind randomized trial of interferon plus colchicine in anti-HCV positive chronic active hepatitis. Hepatology 22, 501A.